Clinical Trial Update: Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation [Phase 2, Phase 3]

View source ↗

Summary

Pfizer conducted a completed Phase 2/Phase 3 trial to evaluate the efficacy and safety of UK-390,957 in men with premature ejaculation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• UK-390,957

Snippet

Sponsor: Pfizer | Conditions: Ejaculation | Phase 2, Phase 3 | Status: COMPLETED